Insights
Insights From Our Experts
Articles
Demystifying Market Access: A Must-Read for Navigating the Lab-to-Patient Journey
Market access is no longer just a final hurdle—it’s a strategic imperative that shapes how therapies reach the patients who need them most. If you’ve ever wondered what it really takes to bring a treatment from…
Webinar: Transformative Commercialization for New BioPharma Entrants Ensuring Success with Capital and Time Efficiency
In a recent EVERSANA webinar, experts Maneesh Gupta, Jennifer Meeuwsen, Anne Marie Robertson, and Iterum Therapeutics CEO Corey Fishman discussed key challenges for first-time biopharma launchers and shared strategies for success. Key challenges: 3x lower net…
EVERSANA Returns as Global Host and Presenting Sponsor for Frontiers Health 2025
Building on its commitment to global health innovation and bringing innovators together from around the globe, EVERSANA returns as the Global Host and Presenting Sponsor of Frontiers Health 2025, which will take place November 11-12 in…
Staying Ahead of the Curve in Pharmacovigilance: CIOMS XIV Draft “Artificial Intelligence in Pharmacovigilance”
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
Staying Ahead of the Curve in Pharmacovigilance: Outcome of GVP Inspections by NPRA
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
Celebrating Excellence: Two EVERSANA Leaders Named 2025 PM360 ELITE 100 Winners
Posted by
on May 9, 20255/9/25
PM360 has announced its 2026 ELITE 100 winners, and two EVERSANA team members are on the list. Daniel Pfeffer, Senior Manager, Data Science, has been recognized in the Data Miner category, and Katie Beller, SVP,…
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor…
Staying Ahead of the Curve in Pharmacovigilance: Emerging Regulations and Their Implications in Saudi Arabia
Our Pharmacovigilance experts actively track evolving global regulations—so you don’t have to. To help simplify pharmacovigilance, we stay ahead of new regulations, assess their impact on current practices, and recommend actions that empower professionals to update…
One Team, One Voice: The Impact of Centralized Medical Content Development
Featured Study – One Team, One Voice The Impact of Centralized Medical Content Development Presented at MAPS 2025. Objective: A survey was conducted to better understand Medical Affairs (MA) professionals’ strategies for medical content development, utilizing…
Maximizing Medical Affairs and MSL Impact: How Choosing a Strategic Launch Partner Propels Success
Medical Science Liaisons (MSLs) serve as the bridge between pharmaceutical companies, healthcare professionals, and the scientific community. Their impact reverberates across the entire healthcare ecosystem as they are essential for fostering scientific dialogue, driving evidence-based medicine,…